TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Recurrent Primary Central Nervous System (CNS) Lymphoma
Source: Primary Central Nervous System Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent Primary Central Nervous System Lymphoma
The prognosis for patients with recurrent CNS lymphoma is poor, with a median survival of 6 to 12 months, but up to 43 to 50 months if autologous stem cell transplant (SCT) consolidation is performed (if not applied previously).[1] This finding implies that deferred autologous SCT until first relapse may still result in longer-term survival. The prognosis is worse for patients 60 years and older, who account for more than 50% of cases.[2]
Treatment options for recurrent primary CNS lymphoma include:
Reinduction therapy followed by SCT.
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice